Prevalence, Mutation Patterns, and Effects on Protease Inhibitor Susceptibility of the L76V Mutation in HIV-1 Protease-Reference-Cited by-同舟云学术

Prevalence, Mutation Patterns, and Effects on Protease Inhibitor Susceptibility of the L76V Mutation in HIV-1 Protease

Published:2010-11 Issue:11 Volume:54 Page:4903-4906
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Young Thomas P.¹,Parkin Neil T.²,Stawiski Eric³,Pilot-Matias Tami⁴,Trinh Roger⁴,Kempf Dale J.⁴,Norton Michael⁴

Affiliation:

1. Abbott Molecular, Des Plaines, Illinois

2. Data First Consulting, Inc., Menlo Park, California

3. Monogram Biosciences, South San Francisco, California

4. Abbott Laboratories, Abbott Park, Illinois

Abstract

ABSTRACTPatterns of HIV-1 protease inhibitor (PI) resistance-associated mutations (RAMs) and effects on PI susceptibility associated with the L76V mutation were studied in a large database. Of 20,501 sequences with ≥1 PI RAM, 3.2% contained L76V; L76V was alone in 0.04%. Common partner mutations included M46I, I54V, V82A, I84V, and L90M. L76V was associated with a 2- to 6-fold decrease in susceptibility to lopinavir, darunavir, amprenavir, and indinavir and a 7- to 8-fold increase in susceptibility to atazanavir and saquinavir.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00906-10

Reference37 articles.

1. Baras, A., K. Champenois, P. Choisy, Y. Yazdanpanah, and L. Bocket. 2009. Factors associated with the L76V protease mutation in HIV-1-infected patients with virological failure of lopinavir/ritonavir. Antivir. Ther.14(Suppl. 1):A114.

2. In Vitro Selection of Mutations in the Human Immunodeficiency Virus Type 1 Reverse Transcriptase That Decrease Susceptibility to (−)-β- d -Dioxolane-Guanosine and Suppress Resistance to 3′-Azido-3′-Deoxythymidine

3. Bierman, W. F., M. A. van Agtmael, M. Nijhuis, S. A. Danner, and C. A. Boucher. 2009. HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review. AIDS23:279-291.

4. High-level resistance to (-) enantiomeric 2'-deoxy-3'-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase

5. Braun, P., H. Walter, D. Hoffmann, M. Däumer, R. Ehret, K. Korn, B. Thiele, T. Berg, M. Stürmer, F. Wiesmann, and R. Kaiser. 2007. Clinically relevant resensitization of protease inhibitors (PIs) saquinavir and atazanavir (ATV) by L76V mutation in multidrug-resistant HIV-1-infected patients. Antivir. Ther.12:S142.

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Web Service for HIV Drug Resistance Prediction Based on Analysis of Amino Acid Substitutions in Main Drug Targets;Viruses;2023-11-11

2. Comprehending the Structure, Dynamics, and Mechanism of Action of Drug-Resistant HIV Protease;ACS OMEGA;2023

3. Comprehending the Structure, Dynamics, and Mechanism of Action of Drug-Resistant HIV Protease;ACS Omega;2023-03-07

4. Role of Bioinformatics in Drug Design and Discovery;Interdisciplinary Biotechnological Advances;2023

5. Process Chemistry Development of the HIV Protease Inhibitor Drug Kaletra: A Mixture of Ritonavir and Lopinavir;Current Drug Synthesis;2022-09-22